Barclays raised the firm’s price target on Fresenius Medical (FMS) to EUR 39 from EUR 38.50 and keeps an Equal Weight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 37.30 from EUR 35.40 at JPMorgan
- Fresenius Medical ADRs initiated with a Buy at Berenberg
- Fresenius Medical Care Reports Strong Q3 2024 Results
- Fresenius Medical Care Unveils New Long-Term Incentive Plan
- Fresenius Medical reports Q3 EPS EUR0.73 vs. EUR0.29 last year